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Abstract
 
One of the most common forms of carcinoma in women, cervical invasive squamous cell car-
cinoma (CIC), often coexists with multiple lesions of cervical intraepithelial neoplasia (CIN).
CIC and CIN show heterogeneity with respect to both histopathology and biology. To under-
stand the causes, origin, and model of progression of cervical carcinoma, we assessed the clonal-
ity of a case with multiple synchronous lesions by analyzing X chromosome inactivation poly-
morphism, human papillomavirus type 16 (HPV16) sequence variation/mutations, and loss of
heterozygosity (LOH). Microdissection was performed on 24 samples from this case, represent-
 
ing the entire lesional situation. The combination of different X chromosome inactivation
patterns, two HPV16 point mutations, and LOH at three genomic microsatellite loci, led to
the identification of five different “monoclonal” lesions (CIN II, CIN III, and invasive carci-
noma nests) and five different “polyclonal” areas (CIN II and normal squamous epithelium).
This finding indicated that CIC can originate from multiple precursor cells, from which some
clones might progress via multiple steps, namely via CIN II and CIN III, whereas others might
develop independently and possibly directly from the carcinoma precursor cells. Our results
also supported the view that HPV16 as a “field factor” causes cervical carcinoma, which is
probably promoted by the loss of chromosomal material as indicated by the LOH.
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Introduction
 
Cervical invasive carcinoma (CIC)
 
*
 
 is one of the most
common malignancies in females. Unlike in some other tu-
mors, so far no specific oncogenes or tumor suppressor
genes have been found in cervical carcinoma. Although
certain specific types of human papillomavirus (HPV) have
been regarded as the main cause of cervical squamous cell
carcinoma (1–3), only a minority of HPV-infected cervices
develop any lesions, including cervical intraepithelial neo-
plasia (CIN) I, CIN II, and CIN III, and CIC (4). CIC
commonly coexists with CINs in the same cervix. CIN le-
sions, which may regress, persist, or progress, are usually
well demarcated from adjacent normal epithelium and have
cells morphologically similar to CIC cells. Elimination of
CINs by surgical intervention reduces the occurrence of
CIC (5, 6).
Consequently, it is assumed that CIC originates from a
single founder cell and that the malignancy progresses by
multiple evolutionary steps via CINs. If this is true, it could
be a key to our understanding of the causes and mecha-
nisms of carcinogenesis of cervical carcinoma and thus be
very helpful in the design of rational prevention and treat-
ment strategies. Clonality analysis has been confirmed to be
a powerful tool with which to tackle this issue. If cervical
carcinoma is monoclonal and the synchronous lesions show
identical clonal patterns, this might favor the assumption
that mutation of oncogenes or tumor suppressor genes is
the cause of cervical carcinoma. Otherwise, it is more
likely that cervical carcinoma is caused by some field factor
such as HPV infection. Although several studies have put
forward evidence supporting the monoclonal model of cer-
vical neoplasia (7–9), there are a few reported cases of cer-
vical carcinoma with contrary molecular features, i.e., signs
of polyclonal origin (7, 8, 10).
 
Address correspondence to Xinrong Hu, Department of Genetics and
Pathology, Rudbeck Laboratory, Uppsala University, SE-751 85 Upp-
sala, Sweden. Phone: 46-18-6113844; Fax: 46-18-502172; E-mail:
hu.xinrong@genpat.uu.se
 
*
 
Abbreviations used in this paper:
 
 CIC, cervical invasive carcinoma; CIN,
cervical intraepithelial neoplasia; HPV, human papillomavirus; HPV16,
human papillomavirus type 16; LOH, loss of heterozygosity. 
846
 
Clonality Analysis of Cervical Carcinoma
 
The X chromosome inactivation pattern in a precursor
cell is invariably inherited by subsequent descendants form-
ing a cell lineage (11–13). The polymorphism of the X
chromosome–linked androgen receptor gene, which con-
sists of a short tandem repeat, [CAG]
 
n
 
 (
 
n 
 
  
 
11 
 
 
 
 31), has
been widely used for clonality analysis of female tumors.
However, interpretation of clonality information obtained
from samples with the same and/or differing X chromo-
some inactivation patterns in an individual requires addi-
tional markers. HPV infection is believed to precede the
initiation of cervical carcinoma and persists in almost all
CIN and CIC lesions (1, 14). Human papillomavirus type
16 (HPV16) is the most commonly seen type of HPV in
cervical squamous cell carcinoma (14) and sequence varia-
tions or mutations are frequent in HPV16 (15–19). If multi-
ple cervical lesions in an individual patient have different
HPV16 variants, this might indicate that they do not share a
clonal origin. Thus, the HPV16 sequence can be one assis-
tant clonality marker. Loss of heterozygosity (LOH) can be
another as it occurs frequently in cervical carcinoma (20).
Indeed, many clonality analyses based on LOH have been
performed (10, 21).
To address the clonality of cervical carcinoma we se-
lected one “golden” case for analysis instead of screening a
large set of cases with statistical power. This case had many
advantages: a CIC synchronous with CIN II and CIN III
lesions; a moderate degree of differentiation so that it was
possible to isolate carcinoma nests from normal tissue; sepa-
rate carcinoma nests were available for easy microdissec-
tion; no conspicuous inflammatory cells infiltrating either
the lesions or normal areas, which could interfere with X
chromosome inactivation and LOH analyses; the patient
had not undergone radiotherapy or chemotherapy before
surgical extirpation; the entire cervix was available, from
which we could take enough samples representing the
whole set-up of cervical lesions observed; the sample was
available as fresh tissue, which was preferable for restriction
enzyme digestion and PCR; and the case was positive for
HPV16 and informative for androgen receptor gene poly-
morphism and three of the screened LOH markers.
The main finding was that this case of cervical carcinoma
was polyclonal. One of the invasive cancer clones could be
traced back to its synchronous CIN II and CIN III lesions,
whereas others had no specific intraepithelial precursors.
This indicated that cervical carcinoma can originate from
multiple precursor cells, from which some malignant clones
might progress via multiple steps, namely CIN II and CIN
III, whereas others might develop independently and possi-
bly directly from the precursor cell. The results also
strongly supported the opinion that HPV16 is the cause of
cervical carcinoma.
 
Materials and Methods
 
Patient and Specimen. 
 
Case H2 was a Swedish woman who
had her uterus removed at the age of 33 because of cervical carci-
noma. Macroscopically, the tumor grew within the cervix and
around the external ostium without involving the uterus body or
vagina. The histopathological diagnosis made after microscopical
examination was CIC (moderate differentiation) with invasion of
local vessels and metastasis to local lymph nodes. 1 mo before the
surgical procedure the patient had been found by vaginal cytol-
ogy to have cervical malignancy. Subsequently this diagnosis had
been confirmed by biopsy. HPV routine testing revealed HPV16
positivity. Before this HPV test, the HPV infectious situation was
not known. At two vaginal cytological examinations 11 and 8 yr
earlier no abnormality had been found. The entire fresh cervix
was cut from the external ostium to the endocervix into six parts
designated A, B, C, D, E, and F, in order. Parts A, C, and E were
used for routine histopathological examinations, whereas B, D,
and F were frozen at 
 
 
 
80
 
 
 
C for research.
 
Microdissection. 
 
6 
 
 
 
m of serial cryosections were prepared
from parts B, D, and F, and stained briefly with Mayer’s hema-
toxylin. Multiple microdissections were performed on invasive
cancer nests CIN II and CIN III, normal epithelium, and glands
and stroma from different areas in a representative section for
each tissue block. Altogether 24 samples (H2-1–24) were taken
covering the whole lesional area. When it was necessary to repeat
Figure 1. Topography and histopathology of microdissected samples.
Sides with F, D, or B (names of tissue block) are external ostium portions
and the opposite sides are facing endocervix. #, H2 ; arrows point to the
foci where samples (named H2-1, -2, etc.) were microdissected; N, nor-
mal squamous epithelium; G, gland epithelium; S, stroma; IC, invasive
carcinoma; Sup. Inv., superficially invasive carcinoma. 
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the microdissection procedure it was done using immediately ad-
jacent sections that represented the same areas as originally chosen
for sampling. Sample number, location, and morphology are
summarized in Fig. 1. All invasive lesions were distinctly demar-
cated from stroma and CINs from adjacent normal epithelium
(Fig. 2). Admixture of normal epithelial, stromal, or inflammatory
cells was insignificant judging by careful examination under the
microscope. Microdissection was performed with a scalpel, and
the blade was changed after each microdissection. The microdis-
sected pieces were transferred to Eppendorf tubes containing 50
 
 
 
l of PCR buffer II (PerkinElmer; Roche Molecular System).
Each sample contained 
 
 
 
500–1,000 cells (22).
 
DNA Preparation and Restriction Enzyme Digestion. 
 
Lysis of
cells overnight by 500 
 
 
 
g/ml of proteinase K at 56
 
 
 
C was inter-
rupted by incubation at 95
 
 
 
C for 10 min. 30 
 
 
 
l of the 50 
 
 
 
l of
roughly prepared DNA from each sample was ready for use by
PCR sequencing of HPV16 (23) and PCR gene scanning detec-
tion of LOH with microsatellite markers (24). The DNA in the
remaining 20 
 
 
 
l was further purified for X chromosome inactiva-
tion analysis (25). 50 
 
 
 
l of 95% EtOH was added and the sample
was incubated at 
 
 
 
70
 
 
 
C for 5 h. After centrifugation at 13,000
rpm for 30 min, the precipitate was washed with 250 
 
 
 
l of 70%
EtOH and spun at 13,000 rpm for 20 min and then air-dried.
The pellet was dissolved in 20 
 
 
 
l of reaction buffer for methyla-
tion-sensitive restriction enzyme HpaII digestion (Promega) and
halved into two tubes. To one portion 15 U of HpaII was added
and incubated overnight at 37
 
 
 
C. The reaction was terminated by
heat inactivation at 95
 
 
 
C for 5 min. The other portion of DNA,
as a control, was not exposed to HpaII but was otherwise treated
in the same way. The non-HpaII–digested and HpaII-digested
DNA portions were used for PCR amplification of the androgen
receptor gene fragment.
 
PCR. 
 
Information on the sequences of PCR primers for the
androgen receptor gene (two pairs), HPV16 genome (17 pairs),
or human microsatellite DNA sequences (three pairs), as well as
the magnesium concentration and the annealing temperature
used for PCR with each primer pair are summarized in Table I.
PCR was performed on a RoboCycler Gradient 96 (Stratagene).
Nested PCR was used to amplify the androgen receptor gene
fragment (26). 20 
 
 
 
l of reaction volume (PCR buffer II, 1.75
mM of MgCl
 
2
 
, 200 
 
 
 
M of each deoxynucleotide, 0.5 U of Taq
Gold DNA polymerase [PE; Roche Molecular System], 2 pmols
 
Table I.
 
Sequences of PCR Primers and PCR Conditions
 
Names of PCR primers Sense primer 5
 
 
 
- Antisense primer 5
 
 
 
- bp [Mg
 
2
 
 
 
] A.T.
 
mM
 
 
 
C
 
X-ch. a.r.
 
P51/-54(outer)
 
gccgtccaagacctaccgaggagc gctgtgaaggttgctgttcctcat
 
305 1.75 60
P52/-53(inner)
 
tccataatctgttccagagcgtgc ggcttggggagaaccatcctcacc
 
226 1.75 61
 
HPV16 (nt)
 
E6-1(24)/-2(646)
 
ctaagggcgtaaccgaaatc tcctcctctgagctgtcatt
 
642 4.0 55
E7-1(505)/-2(892)
 
cgatgtatgtcttgttgcag ttacattccgtaccctcttc
 
387 2.5 55
E1-1(816)/-6(1285)
 
catactaggaattgtgtgcc acctgtaacatctgctgagt
 
489 2.5 55
E1-5(1285)/-2(1800)
 
actcagcagatgttacaggt atgctgctgctgtactacgc
 
515 2.5 55
E1-3(1800)-8(2291)
 
cgtagtacagcagcagcatt acctgtgttagctgcaccat
 
511 2.0 55
E1-7(2291)/-4(2822)
 
atggtgcagctaacacaggt tggtcacgtaggtctgtact
 
551 2.5 55
E2-1(2703)/-2(3190)
 
tcaaggacgtggtccagatt acttgaccctctaccacagt
 
506 4.0 58
E4-1(3190)/-2(3689)
 
tgtggtagagggtcaagttga catgtagacgacactgcagta
 
538 2.5 55
E5-1(3710)/-2(4234)
 
ggcattggacaggacataat cagaacgtttgtgtcgcatt
 
544 4.0 55
L2-1(3999)/-4(4479)
 
ataacagcagcctctgcgtt ggagcaagtgtatctgtagc
 
500 4.0 58
L2-3(4479)/-2(5111)
 
gctacagatacacttgctcc acgcctagaggttaatgctg
 
652 2.5 55
L1.2-1(5111)/L2-6(5639)
 
cagcattaacctctaggcgt actaggcagccaaagagaca
 
548 2.5 55
L1-3(5639)/L1.2-2(6151)
 
tgtctctttggctgcctagt cattggtacatggggatcct
 
532 3.0 58
L1-1(6151)/-4(6601)
 
aggatccccatgtaccaatg ggttaccccaacaaatgcca
 
470 3.0 58
L1-5(6601)/-2(7106)
 
tggcatttgttggggtaacc gtagaggtagatgaggtggt
 
525 2.5 55
LCR-1(7099)/-4(7528)
 
tacacccaccacctcatcta tggcaagcaggaaacgtaca
 
449 2.5 58
LCR-3(7528)/-2(35)
 
tgtacgtttcctgcttgcca tcggttcaaccgatttcggt
 
412 2.5 58
 
Microsatellite markers
 
D3S659
 
ctgcaaggtctgtttaacag attccagggacaagttcccc
 
105 1.5 55
D3S1283
 
ggcagtaccacctgtagaaatg gagtaacagaggcatcgtgtattc
 
156 1.5 55
D6S311
 
atgtcctcattggtgttgtg gattcagagcccaggaagat
 
237 1.5 55
Sequences of PCR primers and PCR conditions. X-ch. a.r., inactivation polymorphism of X chromosome–linked androgen receptor gene; P51–54,
primers for amplification of androgen receptor gene (reference 26); HPV16 (nt), initial nucleotide position of the primers used for amplification of
the HPV16 genome including genes E1, E2, E4, E5, E6, E7, L1, L2, and LTR. We designed the primers according to the reference sequence
(reference 30). The sequences of primers for the microsatellite markers were derived from The Genome Database (references 27–29). bp, length of
PCR fragments; [Mg
 
2
 
 
 
], concentration of MgCl
 
2
 
; A.T., annealing temperature. 
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of each sense and anti-sense primer, and 5 
 
 
 
l of DNA solution
with or without HpaII digestion) was used and 20 cycles (45 s at
95
 
 
 
C, 30 s at 60
 
 
 
C, and 1 min at 72
 
 
 
C) with 10 min initial dena-
turation at 95
 
 
 
C, and 7 min final elongation at 72
 
 
 
C were applied
in the outer PCR. 2 
 
 
 
l of the outer PCR product was then used
for the inner PCR with a 20-
 
 
 
l reaction mix containing the
same concentration of PCR buffer II, MgCl
 
2
 
, each deoxynucle-
otide as listed above, 1 U of Taq Gold, and 5 pmols of inner
primers. One of the inner primers was labeled in the 5
 
 
 
end with a
fluorescent 6-FAM (Applied Biosystems) group to enable detec-
tion of the PCR products in the fragment analysis. We used 30
cycles with the same PCR program as described above, but at a
higher annealing temperature of 61
 
 
 
C for the inner PCR.
To amplify the HPV16 genome, we used 30 
 
 
 
l of reaction
volume (PCR buffer II, MgCl
 
2
 
 [at a concentration specific for
each primer pair, shown in Table I], 200 
 
 
 
M of each deoxynu-
cleotide, 0.5 U of Taq DNA polymerase, 0.5 
 
 
 
M of each sense
and anti-sense primer, and 1 
 
 
 
l of DNA solution). Thirty-five
cycles (1 min at 95
 
 
 
C, 2 min at a temperature specific for each
primer pair [shown in Table I], and 3 min at 72
 
 
 
C) with 10 min
of initial denaturation at 95
 
 
 
C and 7 min of final elongation at
72
 
 
 
C were used.
To amplify microsatellite DNA, a 20-
 
 
 
l mix containing the
components at the same concentrations used for PCR, of
HPV16, 35 cycles (30 s at 95
 
 
 
C, 45 s at 55
 
 
 
C, and 1 min at 72
 
 
 
C)
with 10 min initial denaturation at 95
 
 
 
C, and 7 min final elonga-
tion at 72
 
 
 
C, was used. Amplification of D3S659 (3p13) (27),
D3S1238 (3p24.2-3p22) (28), and D6S311 (6q22-6q23) (29)
were chosen because these loci were informative in this case ac-
cording to our pilot screening. PCR products were labeled by
(R110) dUTP (PerkinElmer) during the PCR cycles.
To avoid contamination, we prepared a PCR master mix in an
isolated room in a hood where UV light was used to destroy any
potential contaminating DNA or PCR product at the working
area before and after this manipulation. Template DNA was
added under similar working conditions in a separate room.
 
Fragment Analysis. 
 
1.5 
 
 
 
l of the final PCR product of an-
drogen receptor gene or a microsatellite locus was mixed with
0.5 
 
 
 
l of loading buffer, 0.5 
 
 
 
l of internal size standard GENE-
SCAN-350 ROX (PerkinElmer), and 2.5 
 
 
 
l of formamide, and
denatured at 95
 
 
 
C for 5 min followed immediately by cooling on
ice before loading on a 4.5% acrylamide gel. Electrophoresis was
performed on an ABI Prism 377 sequencer (PerkinElmer). Size
and quantity of allelic fragments and LOH were analyzed and de-
termined by GeneScan Analysis 2.0.2 (PE; Applied Biosystems).
A 60% or higher allelic signal reduction between any two alleles
after HpaII digestion was considered a homogeneous pattern rep-
resenting a sample with a paternally or maternally inactivated X
chromosome (26). The same criterion of allelic reduction was
adopted for judgement of LOH.
 
Sequence Analysis. 
 
HPV16 PCR amplicons were separated
electrophoretically on 1.5% agarose gel and stained with ethidium
bromide. Desired bands were cut out and subsequently purified
on GenElute Minus EtBr Spin Columns (Supelco). The purified
PCR products were quantified and then applied to enzymatic ex-
tension reactions for DNA sequencing using the Cycle Sequenc-
ing Ready Reaction Kit (Big-Dye terminator reagent containing
dye-labeled terminators; PerkinElmer; Applied Biosystems) in
Figure 2. Representative photos illustrating the microdissection proce-
dure. Upper, before microdissection; lower, after microdissection with
the focus on spaces after the sampling of H2-2–4.
Figure 3. Electropherograms representative of different X chromo-
some inactivation patterns. (1) and (5), without HpaII digestion; (2)–(4)
and (6), with HpaII digestion. (1), two alleles each with different times of
a [CAG] tandem repeat, the short allele (defined as a) giving highest peak
at 208 bp, a second peak at 205 bp, and a third peak at 202 bp, and the
long allele (defined as b) is represented by highest peak at 226 bp, a second
peak at 223 bp, and a third peak at 220 bp; (2), short allele remains, de-
fined as a pattern (H2-3); (3), long allele remains, defined as b pattern
(H2-7); (4), two alleles remain, defined as ab pattern (H2-8); (5), an extra
allele (defined as  a) with highest peak at 196 bp, a second peak at 193
bp, and a third peak at 190 bp; (6), b allele is reduced by 63% and a allele
is reduced by 25% of  a allele, therefore this picture represents  aab pattern
(H2-9). (5) and (6) represent a special pattern seen only in H2-9.849 Hu et al.
GeneAmp PCR Systems 9600 (PerkinElmer). The same forward
and reverse primers used for the PCR amplification of HPV16
were used separately in cycle sequencing. The extension products
were purified by ethanol/sodium acetate precipitation, and then
electrophoresed on an ABI Prism 377 sequencer. The sequence
and variations were analyzed and determined by the Factura™
and Sequence Navigator version 2.0 (PerkinElmer; Applied Bio-
systems). The test was repeated at least once for each sample start-
ing from DNA-PCR amplification with the same result.
Results
X Chromosome Inactivation Patterns.  23 out of 24 non-
HpaII–digested samples showed two alleles (a, 208 bp; b,
226 bp) of the androgen receptor gene and one sample
contained an additional allele ( a, 196 bp) (Fig. 3). The
peaks for the alleles did not overlap in size, which made
the H2 case ideal for analysis of polymorphism of the X
chromosome inactivation-linked androgen receptor gene.
After HpaII digestion, three common X chromosome in-
activation patterns, a,  b, and ab, were seen (Fig. 3). As
shown in Table II, all three samples from normal epithe-
lium, two CIN II samples, and one superficially invasive
carcinoma sample had ab; one CIN II, one CIN III, one
superficially invasive cancer sample, six invasive carcinoma
samples, and all gland and stroma samples displayed a; and
three invasive carcinoma samples displayed b. A CIN II
Table II. X Chromosome Inactivation Pattern, HPV16 Sequence Variations and Mutations, and LOH of the Microdissected Samples
HPV16 sequence variants LOH
Sam.
(H2-)
Histo-
pathol.
Tissue
block Xc. pat.
E2(nt
2926)
E2(nt
3800)
L2(nt
5226)
L1(nt
6318)
LCR(nt
7707) V
D3S
659
D3S
1283
D6S
311
1 Sq. ep. F ab gg     c c — g V2 d d d
2 Sq. ep. F ab g—c— g V 1 ddd
3 CIN III F a g—c— g V 1 sll
4 Inv. ca. F b ggc —g V 2 s l l
5 Inv. ca. F b ggc —g V 2 s l l
6 Inv. ca. F a g—c— g V 1 sll
7 Inv. ca. F b g—c— g V 1 sls
8 Sup. inv. F ab g—c— g V 1 ddd
9 CIN II F  aab g—c t g V 3 sll
10 Gland F a ng ng ng ng ng ng d d d
11 Stroma F a ng ng ng ng ng ng d d d
12 Sq. ep. D ab g—c— g V 1 ddd
13 CIN II D a g—c— g V 1 sll
14 Inv. ca. D a g—c— g V 1 sdl
15 CIN II B ab g—c t g V 3 sll
16 CIN II B ab g—c t g V 3 sdl
17 Inv. ca. B a g—c— g V 1 sll
18 Stroma B a ng ng ng ng ng ng d d d
19 Sup. inv. B a g—c— g V 1 sdl
20 Inv. ca. B a g—c— g V 1 sdl
21 Inv. ca. B a g—c— g V 1 sll
22 Inv. ca. D a g—c— g V 1 sll
23 Inv. ca. D a g—c— g V 1 dll
24 Gland F a ng ng ng ng ng ng d d d
HPV16 refer. seq. (reference 30) a c a c a
Amino acid change q57q q349e l330f s253f
X chromosome inactivation pattern, HPV16 sequence variations and mutations, and LOH of the microdissected samples. Sq. ep., normal squamous
epithelium; Sup. Inv., superficially invasive carcinoma; Xc. pat., X chromosome inactivation patterns (a, b, ab, aab);  , the same nucleotide as the
reference nucleotide at this position; ng, negative for HPV. q57q, the left q is the reference amino acid, the 57 is the codon position, and the right q
is the amino acid resulting from the nucleotide shift found at this codon. Thus, q57q is a silent change, whereas the other three nucleotide changes
are missense variations or mutations. V, HPV16 variant; s, short allele remains; l, long allele remains; d, both alleles remain and therefore normal.850 Clonality Analysis of Cervical Carcinoma
sample (H2-9) was special. It seemed to have an extra al-
lele. After HpaII digestion of this sample the two regular
alleles were cut to different degrees but the additional allele
could not be cut (Fig. 3). This fact indicated that although
the emergence of the extra allele represented a true allele,
it was not the result of contamination of a male or a homo-
geneous female DNA.
DNA Sequence Variations and Mutations of the HPV16 Ge-
nome.  The entire genome of HPV16 with 7,905 bp was
PCR sequenced for 20 out of 24 samples (the other four
were HPV16 negative). Any nucleotide differing from that
of the reference HPV16 sequence (30) is described here as
a variation (probably occurring before infecting a specific
host) or a mutation (probably occurring inside a specific
host). Three variations and two mutations were found in
this case (Table II). The first variation was a silent change
from A to G within E2 (nt 2926). The second was a mis-
sense variation within L2 (nt 5226), in which nucleotide A
was shifted to C (l330f). The last was a shift of A to G at nt
7707 within the long control region. The three variations
were seen in all 20 HPV16-positive samples. The two mu-
tations recorded were missense mutations and found only
in a fraction of the samples. The first was at nt 3800 within
E2 (Fig. 4), in which G replaced C (q349e). This change
was present only in one sample from normal epithelium
(H2-1) and in two invasive carcinoma (H2-4 and H2-5)
samples. The second was a shift from C to T at nt 6318
within L1 (Fig. 4) (s253f), present only in three CIN II
samples (H2-9, H2-15, and H2-16).
If an HPV16 “variant” is defined as an HPV16 genome
with at least one different nucleotide within the whole se-
quence (22, 30), three HPV16 variants (V1–3) were found
(Table II). V1 was the variant with the three common se-
quence variations as described above and was distributed
among most of the samples; V2 had the three sequence
variations in addition to the mutation in E2 (nt 3800); and
V3 had the three sequence variations in addition to the
mutation in L1 (nt 6318).
LOH.  Analysis was successful and informative for
D3S659 (101 bp, 105 bp), D3S1283 (150 bp, 156 bp), and
D6S311 (231 bp, 237 bp) in all samples (Fig. 5). Loss of the
long allele for D3S659 and of the short allele for D3S1283
occurred. Most samples with LOH at D6S311 had lost the
short allele, whereas one had lost the long allele. None of
the normal samples, squamous epithelium, gland and
stroma, nor the superficially invasive carcinoma sample
(H2-8), showed loss at any of these three microsatellite
Figure 4. Electropherograms showing missense mutations of the
HPV16 sequence. (1) and (3), reference sequences of HPV16 E2 (H2-2)
and L1 (H2-2), respectively; (2), G replaced C at nt 3800 within E2
(H2-5); (4), T replaced C at nt 6318 within L1 (H2-9).
Figure 5. Electropherograms showing LOH analyzed at three different
microsatellite loci. (1), (5), and (8) are normal tissue (H2-2), and the others
are CIN or invasive carcinoma samples. (1)–(4), D6S311 (231 bp, 237 bp);
(2), long allele remains (H2-3); (3), short allele remains (H2-7); (4), both al-
leles remain (H2-8); (5)–(7), D3S659 (101 bp, 105 bp); (6), short allele re-
mains (H2-3); (7), both alleles remain (H2-8); (8)–(10), D3S1283 (149 bp,
156 bp); (9), long allele remains (H2-3); (10), both alleles remain (H2-8).851 Hu et al.
markers. The detailed information showing that LOH oc-
curred in most lesion samples is given in Table II.
Clonality Status Defined by Combined Analysis of Three
Clonality Markers.  The carcinoma cell populations with
different X chromosome inactivation patterns were defi-
nitely induced from cells with different clonality status.
However, samples with identical X chromosome inactiva-
tion patterns could not be proven in this way to share the
clonality status. HPV16 variants and LOH markers helped
us to identify the clonality status of the samples having
identical X chromosome inactivation patterns. As shown
in Fig. 6, altogether four different monoclonal families (a1,
a2,  a3,  b6, and b7) and five different polyclonal tribes
(a6b1, a8b3, a9b4, and –aa10b5) were determined by the
combination of the three markers. One sample of mor-
phologically normal squamous epithelium with HPV in-
fection represented an additional polyclonal tribe (a7b2).
The samples from two normal glandular and two stromal
areas contained the a pattern and were negative for both
HPV16 infection and LOH.
Plane Topography of the Different Clonal Lesions.  The
plane topography of the different clonal lesions is illus-
trated by schematic drawings of sections from the tissue
blocks (Fig. 7). When observed in two dimensions some
members with the same clonal status could be seen close
to each other, whereas others were further away from
each other.
Discussion
The results clearly indicated that this case of cervical car-
cinoma originated from multiple precursor cells, and that
the process of carcinogenesis could take either multiple
steps via CINs, or develop independently and directly into
carcinoma from normal precursors. The results also indi-
cated that HPV16 was the direct cause of this cervical car-
cinoma because HPV, as the field factor, must have been
present in multiple target cells (defined by their X chromo-
some inactivation pattern) that not only yielded different
clones of cervical carcinoma but also morphologically nor-
mal epithelium. When abnormally stimulated, as by HPV
infection, and reinforced as by loss of crucial tumor sup-
pressor genes, local stem cells might become tumor precur-
sor cells (31) from which the neoplasm develops. The pat-
tern of X chromosome inactivation in addition to the
HPV16 mutations and the LOH at the three genomic loci,
were regarded as a reflection of the clonality status of the
respective samples. With this information at hand the deri-
vation of the samples from different precursor cells could
be deduced.
Two neighboring normal glandular areas and two sepa-
rate samples of stroma, all of which showed the a pattern of
X chromosome inactivation, might not represent a “mono-
clonal” origin, but rather a skewed distribution of the pro-
genitor cells with the a pattern of X chromosome inactiva-
tion in the normal mosaic (32). Three areas of normal
Figure 6. Chart of clonality status. Xc. patterns, X
chromosome inactivation patterns; a or b, represents
the X chromosome–inactivated allele(s) of the androgen
receptor gene; dashes or lines, indicate the suggested
order in which the different events have occurred;
arrows, symbolize that the HPV16 mutants were sup-
posed to be derived from the V1 variant, and that the
lesions or normal samples originated from different
precursor cells; V, HPV16 variants;  , positive for
HPV16 or LOH;  , negative for HPV16 or LOH.
 *, loss of another allele compared with the common
one from the other samples in this case; #, H2-; (g),
gland; (s), stroma; (sq), normal squamous epithelium.852 Clonality Analysis of Cervical Carcinoma
squamous epithelium displayed polyclonal patterns indicat-
ing that the squamous epithelium of this case was a fine
mosaic of cell clones.
In this case all invasive carcinoma nests but one showed a
monoclonal X chromosome inactivation pattern (a or b).
The one (H2-8) with ab pattern might have been contami-
nated by normal epithelial cells when microdissection was
performed, as the dissected area was a superficial cancer
nest adjacent to normal cells. Unlike all CINs and 11 out of
12 carcinoma samples, neither H2-8 nor any of the normal
samples showed allelic loss at any of the three loci observed.
This result further supports the assumption that H2-8 had
become contaminated with normal cells.
One interesting CIN II sample, H2-9, had the –aab pat-
tern. The extra –a allele was probably produced by micro-
satellite instability in the early stage (CIN II) of cervical
carcinoma and appeared not to affect the carcinogenesis as
it seemed to be limited to only one of the CIN II lesions.
This sample was completely different from all other sam-
ples in its clonality pattern, which in addition to the find-
ing of two different polyclonal CIN II samples, reinforces
the conclusion that this case of cervical carcinoma was of
polyclonal origin.
The HPV16 positivity in all lesions and squamous epi-
thelium samples in this case indicated that the HPV infec-
tion had occurred before the initiation of any lesion.
HPV16 is known to infect squamous cells specifically (33).
Consistent with this, the glandular and stromae samples in
this case were HPV16 negative. The two nucleotide
changes observed in V2 (nt 3800) and V3 (nt 6318), re-
spectively, might be very rare in the infectious HPV16
pool as they have not yet been reported by others. More-
over, the changes were additional to those in V1 and each
appeared independently in a small proportion of the sam-
ples. Therefore, they were regarded as mutations. Most re-
ported cases of cervical carcinoma have contained both
episomal and integrated HPV16 (34–37). The case analyzed
here probably also contained both episomal and integrated
HPV16. With a pair of “back-back” primers in L1 of
HPV16 and “long-PCR” technique, amplicons of 7.9 kb
(indicating the complete circle episomal HPV16 genome),
2 kb, and 0.6 kb (representing at least three copies of
HPV16 joined together in a tail to head fashion with nu-
merous intermediate sequence deletions, which can occur
in an integrated form of HPV16) were obtained in this case
(H2) (unpublished data). Each integrated HPV16 variant in
precursor cells can be passed down to the progeny in a sin-
gle copy by cell division, whereas the episomal form of an
HPV16 variant will be replicated to yield many copies that
are divided between the two daughter cells. HPV residing
in undifferentiated cells, such as tumor cells or tumor pre-
cursor cells, usually cannot produce complete infectious vi-
ral particles capable of infecting neighboring cells because
the capsid proteins, L1 and L2, of HPV cannot be fully ex-
pressed in undifferentiated cells (38). So, if an HPV muta-
tion occurs in (or a different HPV variant infects) tumor
precursor cells, it might be passed down specifically to the
progeny and remain long enough to become detected.
Based on this assumption, the HPV16 variants were used
here as assistant clonality markers.
LOH occurs quite often in cervical carcinoma (39). At
some loci it starts in an early stage of the carcinogenic pro-
cess and is nonrandom in nature (40). The three markers
used in this study evidenced LOH in all CIN II and CIN
III samples from this case, which suggested that the losses at
these loci were early events. They helped us to divide or
prove the clonality status of the samples determined by X
chromosome inactivation patterns and HPV16 variants.
Since all of the clonality markers used appeared during
an early stage of the carcinogenesis (in morphologically
normal epithelium or CINs) as described above, the clonal-
ity information obtained could merely be a reflection of the
clonality of precursor cells. To what degree the results re-
flect the development of subclones occurring in the evolu-
tion of cervical carcinoma is not known. To elucidate this
Figure 7. Plane topography of the different clonal lesions. #, samples
(H2-); a1, a2, a3, b6, or b7, the names of different clonal families. Samples
with same color share the clonality patterns. Red, a1 (a,v1,s,l,l, in the or-
der of X chromosome inactivation pattern; HPV16 variant; LOH pattern
at D6S311; LOH pattern at D3S659; and LOH pattern at D3S1283);
black, a2 (a,v1,d,l,l); yellow, a3 (a,v1,s,d,l); blue, b6 (b,v2,s,l,l); violet, b7
(b,v1,s,l,s). The normal samples are not given labels and the polyclonal le-
sion samples are not given color.853 Hu et al.
exhaustively, a control study such as the investigation of
multiple subclones from a single tissue culture of an HPV-
related tumor, can be done to determine if the clonality, al-
lelic assays, and HPV sequence information were uniform
in a monoclonal system over time.
Both monoclonality (41, 42) and polyclonality (7, 10) of
tumors, including cervical carcinoma, have been reported,
although most published data suggest the monoclonal
model. Even though our results support the polyclonal ori-
gin of cervical squamous cell carcinoma, they could not ex-
clude the possibility that a proportion of cervical carcinoma
cases are monoclonal. To elucidate this issue, detailed anal-
ysis of more cases with synchronous lesions is necessary.
Two recently published articles that deal with the subject
of instability of X chromosome methylation in aberrant
crypt foci of human colon and in lung cancer cells should
also be noted (43, 44). It is not yet known if this phenome-
non occurs in tumors and if it can affect the appropriate
methylation of the X chromosome–linked androgen recep-
tor gene in cervical carcinoma.
The members of each clonal lesion in this case were not
always located close to each other in the plane of the sec-
tion (Fig. 7). This does not necessarily indicate a lack of to-
pographical relation between clonal members, although a
topography in three dimensions needs to be constructed to
address this issue. However, this goes beyond the aim of
the present work.
In summary, our findings of polyclonality of cervical car-
cinoma support the opinion that HPV16 infection is the
cause of cervical carcinoma. A conceivable scheme for the
carcinogenesis of cervical carcinoma is that HPV16 infects
precursor cells at an appropriate location such as the trans-
formation zone and/or in a suitable epigenetic situation.
Those cells might then acquire LOH and develop into in-
dependent CINs or directly initiate CIC. For the CIN le-
sions some unclear additional factors would decide their
fate: to regress, to persist, or to progress. Those HPV16-
infected precursor cells that lack propitious conditions for
carcinogenesis would still give rise to normal epithelium,
which may explain why only a minority of HPV16-posi-
tive cases develop any cervical lesion, and why in a case of
cervical carcinoma with synchronous lesions at different
stages, some of the normal squamous epithelium can be
HPV16 positive, as are the lesions.
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